for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Astellas Pharma Inc

4503.T

Latest Trade

1,699.50JPY

Change

-9.50(-0.56%)

Volume

3,681,000

Today's Range

1,684.00

 - 

1,732.50

52 Week Range

1,375.00

 - 

1,987.00

As of on the Tokyo Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
1,709.00
Open
1,732.50
Volume
3,681,000
3M AVG Volume
108.21
Today's High
1,732.50
Today's Low
1,684.00
52 Week High
1,987.00
52 Week Low
1,375.00
Shares Out (MIL)
1,857.41
Market Cap (MIL)
3,181,794.00
Forward P/E
15.36
Dividend (Yield %)
2.34

Next Event

Dividend For 4503.T - 21.0000 JPY

Latest Developments

More

FDA Approves First Treatment For A Form Of Bladder Dysfunction In Patients As Young As 2 Yrs Of Age

Amgen Establishes Wholly-Owned Affiliate In Japan

Cytomx Therapeutics Says Co And Astellas Announce Strategic Collaboration

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Astellas Pharma Inc

Astellas Pharma Inc. is a Japan-based company mainly engaged in the research, development, manufacture and sales of pharmaceutical products. The Company is involved in the manufacture and sale of pharmaceutical products in Japan, the United States, Europe, China, Korea, Taiwan and other markets through its subsidiaries. Its main products include immunosuppressive drug Prograf, overactive bladder agent Vesicare, Protopic ointment for atopic dermatitis, Harnal for prostatic and urethral smooth muscle, and antimycotic agent Funguard, among others. It also provides pharmaceutical products for gastritis, osteoporosis, hypertension, schizophrenia, rheumatoid arthritis, atopic dermatitis and other diseases. The Company also engages in the research and development of ophthalmology pharmaceuticals through its subsidiaries.

Industry

Major Drugs

Contact Info

2-5-1, Nihombashihon-cho

CHUO-KU, TKY

103-8411

Japan

+81.3.32443000

https://www.astellas.com/jp/

Executive Leadership

Yoshihiko Hatanaka

Chairman of the Board, Chairman of the Board of Directors, Representative Director

Kenji Yasukawa

President, Chief Executive Officer, Representative Director

Naoki Okamura

Vice President, Representative Director

Yukio Matsui

Senior Managing Executive Officer

Fumiaki Sakurai

Senior Managing Executive Officer

Key Stats

2.09 mean rating - 11 analysts
Sell
Hold
Buy
Revenue (MM, JPY)

2018

1.3K

2019

1.3K

2020

1.3K

2021(E)

1.3K
EPS (JPY)

2018

81.110

2019

115.050

2020

104.150

2021(E)

113.737
Price To Earnings (TTM)
17.11
Price To Sales (TTM)
2.50
Price To Book (MRQ)
2.43
Price To Cash Flow (TTM)
12.49
Total Debt To Equity (MRQ)
33.97
LT Debt To Equity (MRQ)
15.94
Return on Investment (TTM)
12.20
Return on Equity (TTM)
8.96

Latest News

Latest News

BRIEF-Astellas Pharma Says Final Prosper Results Show Xtandi Significantly Extends Overall Survival In Men With Non-Metastatic Castration-Resistant Prostate Cancer

* FINAL PROSPER RESULTS SHOW XTANDI SIGNIFICANTLY EXTENDS OVERALL SURVIVAL IN MEN WITH NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER Source text for Eikon: Further company coverage:

BRIEF-FDA Approves First Treatment For A Form Of Bladder Dysfunction In Patients As Young As 2 Yrs Of Age

* FDA APPROVES FIRST TREATMENT FOR A FORM OF BLADDER DYSFUNCTION IN PEDIATRIC PATIENTS AS YOUNG AS 2 YEARS OF AGE

BRIEF-Astellas Pharma Says European Medicines Agency Accepts Astellas' Marketing Authorization Application For Roxadustat

* ASTELLAS PHARMA INC - EUROPEAN MEDICINES AGENCY ACCEPTS ASTELLAS' MARKETING AUTHORIZATION APPLICATION FOR ROXADUSTAT Source text for Eikon: Further company coverage:

BRIEF-Cytokinetics - Co, Astellas Pharma Entered Two Agreements, Which Amend And Restate Co's Research, Development Commercialization Collaboration

* CYTOKINETICS - CO, ASTELLAS PHARMA INC. ENTERED TWO AGREEMENTS, WHICH AMEND AND RESTATE CO'S RESEARCH, DEVELOPMENT COMMERCIALIZATION COLLABORATION

BRIEF-Astellas Pharma Announces Acceptance Of Xospata For Regulatory Review In China By National Medical Products Administration

* ASTELLAS PHARMA INC ANNOUNCES ACCEPTANCE OF XOSPATA (GILTERITINIB) FOR REGULATORY REVIEW IN CHINA BY NATIONAL MEDICAL PRODUCTS ADMINISTRATION Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)

BRIEF-Amgen Establishes Wholly-Owned Affiliate In Japan

* CONSUMMATED PURCHASE FROM ASTELLAS OF 49% OF SHARES OF AMGEN ASTELLAS BIOPHARMA K.K., JOINT VENTURE BETWEEN CO AND ASTELLAS Source text for Eikon: Further company coverage:

BRIEF-Cytomx Therapeutics Says Co And Astellas Announce Strategic Collaboration

* CYTOMX THERAPEUTICS AND ASTELLAS ANNOUNCE STRATEGIC COLLABORATION TO DEVELOP PROBODY® T-CELL ENGAGING BISPECIFIC THERAPIES FOR TREATMENT OF CANCER

BRIEF-Astellas, Pfizer's Xtandi Demonstrates Significant Improvement In Overall Survival In Late-Stage Trial

* XTANDI® (ENZALUTAMIDE) DEMONSTRATES SIGNIFICANT IMPROVEMENT IN OVERALL SURVIVAL IN PHASE 3 PROSPER TRIAL OF PATIENTS WITH NMCRPC Source text for Eikon:

BRIEF-Seattle Genetics, Astellas Says 73% Of Bladder Cancer Patients On Padcev Had Confirmed Tumor Response

* SEATTLE GENETICS AND ASTELLAS ANNOUNCE UPDATED RESULTS FROM PHASE 1B/2 TRIAL OF PADCEV™ (ENFORTUMAB VEDOTIN-EJFV) IN COMBINATION WITH IMMUNE THERAPY PEMBROLIZUMAB AS INVESTIGATIONAL FIRST-LINE TREATMENT FOR ADVANCED BLADDER CANCER

UPDATE 2-Astellas Pharma keeps profit forecast as prostate cancer drug sales rise

Japan's Astellas Pharma Inc reiterated its full-year operating profit forecast on Friday, as a jump in sales of its prostate cancer drug Xtandi countered overseas acquisition costs.

Astellas Pharma 9M operating profit rises 14% to 238 bln yen

Japan's Astellas Pharma Inc said operating profit rose 14% to 238 billion yen ($2.17 billion) in the nine months ending Dec. 31 and it maintained its full-year forecast.

Astellas ramps up M&A, buys U.S. biotech Xyphos for as much as $665 million

Astellas Pharma Inc <4503.T> has bought U.S.-based Xyphos Biosciences Inc to expand its immuno-oncology business, a deal worth up to $665 million including potential development milestones and its second acquisition announced this month.

UPDATE 1-Astellas ramps up M&A, buys U.S. biotech Xyphos for as much as $665 mln

* Deal consists of $120 mln upfront, rest in milestone payments

FDA grants accelerated approval for Astellas, Seattle Genetics' bladder cancer drug

(This December 18 story corrects third paragraph to remove reference to Padcev being the first FDA approved drug for advanced or metastatic urothelial cancer)

UPDATE 1-FDA approves expanded label for Pfizer, Astellas' prostate cancer therapy Xtandi

The U.S. Food and Drug Administration has approved Pfizer Inc and Astellas Pharma Inc's Xtandi to treat patients with a type of prostate cancer, the companies said on Monday.

FDA approves expanded label for Pfizer, Astellas' prostate cancer Xtandi

The U.S. Food and Drug Administration has approved Pfizer Inc and Astellas Pharma Inc's Xtandi to treat patients with a type of prostate cancer, the companies said on Monday.

Japan's Astellas to buy Audentes for $3 billion in high-priced gene therapy bet

Japan's Astellas Pharma Inc <4503.T> is buying U.S. drugmaker Audentes Therapeutics Inc <BOLD.O> for about $3 billion in cash, in a high-priced push to make genetic medicines a key area of growth.

CORRECTED-Japan's Astellas Pharma to buy Audentes Therapeutics for $2.7 bln

Japan's Astellas Pharma Inc said on Monday it had agreed to buy Audentes Therapeutics Inc for $2.7 billion in cash as it looks to bolster its position in the gene therapy market.

Seattle Genetics, Astellas drug rapidly shrinks tumors in bladder cancer study

An experimental drug developed by Seattle Genetics Inc and Astellas Pharma Inc led to significant, rapid tumor shrinkage in patients with advanced bladder cancer who had been previously treated with immunotherapy and chemotherapy in a midstage trial, according to data presented...

CORRECTED-Seattle Genetics, Astellas drug shows rapid tumor shrinkage in advanced bladder cancer study

An experimental drug developed by Seattle Genetics Inc and Astellas Pharma Inc led to significant, rapid tumor shrinkage in patients with advanced bladder cancer who had been previously treated with immunotherapy and chemotherapy in a midstage trial, according to data presented...

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up